Our findings are consistent with previous clinical and preclinical studies, which demonstrated that MXD3 was highly expressed in neuroblastoma and medulloblastoma cells [30], [31], and it was associated with high-risk features [30]. This evidence concerns the gene MXD3 and medulloblastoma.